title: Three patients with hemophagocytic syndrome who developed acute organic brain syndrome.
abstract: BACKGROUND
  We describe three patients with hemophagocytic syndrome (HPS) who developed acute organic brain syndrome. All three presented with high-grade fever and twilight state, and were admitted to our hospital. After admission, delirium developed in all three. As delirium improved, various other psychiatric symptoms, including hallucinations, agitation, hypoactivity, affective lability and insomnia, were noted.
  
  
  CONCLUSIONS
  When treated with steroid hormones, immunoglobulin and neuroleptics, all patients demonstrated improvement in their psychiatric symptoms, as well as in their general condition and laboratory findings. Ultimately, they all recovered and were discharged.
  
  
  CONCLUSIONS
  It needs to be noted that organic brain syndrome might be observed at the onset of HPS. Consequently, early diagnosis and treatment for psychiatric symptoms, as well as for HPS, are crucial.
authors.affiliation: Department of Psychiatry, National Hospital Organization Kure Medical Center, Kure, Hiroshima 737-0023, Japan. shinnoh@med.shimane-u.ac.jp <shinnoh@med.shimane-u.ac.jp>
authors.forename: Hideto
authors.initials: H
authors.lastname: Shinno
authors.forename: Satoshi
authors.initials: S
authors.lastname: Hikasa
authors.forename: Tatsuo
authors.initials: T
authors.lastname: Matsuoka
authors.forename: Hidekazu
authors.initials: H
authors.lastname: Fujita
authors.forename: Osamu
authors.initials: O
authors.lastname: Yamamoto
authors.forename: Minoru
authors.initials: M
authors.lastname: Takebayashi
authors.forename: Youzou
authors.initials: Y
authors.lastname: Uchida
authors.forename: Tetsuo
authors.initials: T
authors.lastname: Nishiura
authors.forename: Jun
authors.initials: J
authors.lastname: Horiguchi
mesh_terms: D000208:Acute Disease; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D014150:Antipsychotic Agents / Q000008:administration & dosage; D001853:Bone Marrow / Q000473:pathology; D001921:Brain / Q000473:pathology; D003693:Delirium / Q000175:diagnosis* / Q000188:drug therapy / Q000523:psychology*; D003937:Diagnosis, Differential; D004292:Dominance, Cerebral / Q000502:physiology; D004569:Electroencephalography / Q000187:drug effects; D005260:Female; D006220:Haloperidol / Q000008:administration & dosage; D006801:Humans; D007262:Infusions, Intravenous; D051359:Lymphohistiocytosis, Hemophagocytic / Q000175:diagnosis* / Q000188:drug therapy / Q000523:psychology*; D008279:Magnetic Resonance Imaging; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage; D019965:Neurocognitive Disorders / Q000175:diagnosis* / Q000188:drug therapy / Q000523:psychology*
chemical_list: D000893:Anti-Inflammatory Agents; D014150:Antipsychotic Agents; D006220:Haloperidol; D008775:Methylprednisolone